Cargando…

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitor in the treatment of patients with nonsmall cell lung cancer

This study aimed to examine the effectiveness of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in treating patients with nonsmall cell lung cancer (NSCLC), and the association between clinical characteristics and effectiveness. This retrospective study included 140 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xi, Li, Wen-Bo, Luo, Qiang, Liu, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10519542/ https://www.ncbi.nlm.nih.gov/pubmed/37747005 http://dx.doi.org/10.1097/MD.0000000000035081

Ejemplares similares

Baseline, Trend, and Normalization of Carcinoembryonic Antigen as Prognostic Factors in Epidermal Growth Factor Receptor-Mutant Nonsmall Cell Lung Cancer Patients Treated With First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Chen, Yu-Mu, et al.
Publicado: (2015)

Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor–mutated lung adenocarcinoma
por: Li, Chi-Cheng, et al.
Publicado: (2020)

Gender-Based Impact of Epidermal Growth Factor Receptor Mutation in Patients With Nonsmall Cell Lung Cancer and Previous Tuberculosis
por: Chang, Chia-Hao, et al.
Publicado: (2015)

Is it feasible to detect epidermal growth factor receptor mutations in circulating tumor cells in nonsmall cell lung cancer?: A meta-analysis
por: Liu, Yafang, et al.
Publicado: (2016)

EGFR mutation testing in blood for guiding EGFR tyrosine kinase inhibitor treatment in patients with nonsmall cell lung cancer: A protocol for systematic review and meta-analysis
por: Yuan, Jin-Qiu, et al.
Publicado: (2017)

High fibrinogen-albumin ratio index predicts poor prognosis for lung adenocarcinoma patients undergoing epidermal growth factor receptor-tyrosine kinase inhibitor treatments
por: Zhao, Xiayan, et al.
Publicado: (2020)

Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report
por: Liu, Jing, et al.
Publicado: (2021)

Efficacy of treatment for acneiform eruptions related to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC): A protocol of systematic review and network meta-analysis
por: He, Canfeng, et al.
Publicado: (2021)

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatment: A cohort study
por: Yu, Yuman, et al.
Publicado: (2021)

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020)

Thoracic stereotactic body radiation therapy plus first-line tyrosine kinase inhibitors for patients with epidermal growth factor receptor-mutant polymetastatic non-small-cell lung cancer: A propensity-matched retrospective study
por: Wang, Xia, et al.
Publicado: (2021)

A comprehensive bioinformatics analysis of FOXP3 in nonsmall cell lung cancer
por: Zhu, Jianfei, et al.
Publicado: (2022)

A meta-analysis of the association between BRAF mutation and nonsmall cell lung cancer
por: Cui, Guanghui, et al.
Publicado: (2017)

The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature
por: Ding, Lin, et al.
Publicado: (2016)

Efficacy and safety of icotinib in the treatment of advanced EGFR mutation-positive nonsmall cell lung cancer: A meta-analysis of randomized controlled trials
por: Li, Dailong, et al.
Publicado: (2022)

Efficacy of Addition of Antiangiogenic Agents to Taxanes-Containing Chemotherapy in Advanced Nonsmall-Cell Lung Cancer: A Meta-Analysis and Systemic Review
por: Sheng, Jin, et al.
Publicado: (2015)

Clinical and prognostic significance of Merkel cell polyomavirus in nonsmall cell lung cancer
por: Kim, Gun-Jik, et al.
Publicado: (2017)

Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study
por: Tseng, Li-Chuan, et al.
Publicado: (2020)

Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer
por: Gong, Juejun, et al.
Publicado: (2021)

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis
por: Huang, Wu Feng, et al.
Publicado: (2015)

Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer
por: Hu, Weiheng, et al.
Publicado: (2016)

(125)I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy
por: Xiang, Zhanwang, et al.
Publicado: (2015)

The Efficacy and Safety of Chemotherapy in Patients With Nonsmall Cell Lung Cancer and Interstitial Lung Disease: A PRISMA-Compliant Bayesian Meta-Analysis and Systematic Review
por: Chen, Yu Jie, et al.
Publicado: (2015)

Bmi-1 overexpression as an efficient prognostic marker in patients with nonsmall cell lung cancer
por: Zhang, Xiaojun, et al.
Publicado: (2017)

Epidermal growth factor receptor (EGFR) inhibitor induced purpuric drug eruption: Three case reports
por: Fang, Szu-Yun, et al.
Publicado: (2019)

Circulating long noncoding RNA GAS5 is a novel biomarker for the diagnosis of nonsmall cell lung cancer
por: Liang, Wenjun, et al.
Publicado: (2016)

Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study
por: Ni, Yang, et al.
Publicado: (2016)

Effect of mu Agonists on Long-Term Survival and Recurrence in Nonsmall Cell Lung Cancer Patients
por: Wang, Kai, et al.
Publicado: (2015)

A meta-analysis of efficacy and safety of antibodies targeting PD-1/PD-L1 in treatment of advanced nonsmall cell lung cancer
por: Wang, Cuihua, et al.
Publicado: (2016)

The Efficacy of Combining EGFR Monoclonal Antibody With Chemotherapy for Patients With Advanced Nonsmall Cell Lung Cancer: A Meta-Analysis From 9 Randomized Controlled Trials
por: Sheng, Jin, et al.
Publicado: (2015)

Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials
por: Zhou, Guo-Wu, et al.
Publicado: (2016)

CXCL14 and NOS1 expression in specimens from patients with stage I–IIIA nonsmall cell lung cancer after curative resection
por: Ji, Xiaoqin, et al.
Publicado: (2018)

The Efficacy of Erlotinib Versus Conventional Chemotherapy for Advanced Nonsmall-Cell Lung Cancer: A PRISMA-Compliant Systematic Review With Meta-Regression and Meta-Analysis
por: Ma, Hu, et al.
Publicado: (2016)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

First-line pemetrexed and carboplatin plus anlotinib for epidermal growth factor receptor wild-type and anaplastic lymphoma kinase-negative lung adenocarcinoma with brain metastasis: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis
por: Gu, Biao, et al.
Publicado: (2016)

Expression of Human Epidermal Growth Factor Receptor-2 in Resected Rectal Cancer
por: Meng, Xiangjiao, et al.
Publicado: (2015)

CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study
por: Zhao, Tongwei, et al.
Publicado: (2016)

Is surgery indicated for elderly patients with early stage nonsmall cell lung cancer, in the era of stereotactic body radiotherapy?
por: Nguyen, Nam P., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a7g931j6p4opuco9j9r6a1c1f8